Nicholas Hugh Meryon Insall

Founded in 1996, Shire Holdings Europe Ltd. is a subsidiary of Takeda Pharmaceutical Co., Ltd. and functions as an investment holding British company. The company is based in London, UK.

Founded in 2002, Shire Pharmaceuticals Services Ltd. is a subsidiary of Takeda Pharmaceutical Co., Ltd. that manufactures and distributes pharmaceutical products. The company is based in London, UK.

Part of Takeda Pharmaceutical Co., Ltd., Baxalta UK Investments Ltd. wholesales pharmaceutical goods. The company is based in London, UK.

Founded in 2001, Shire Investments & Finance (U.K.) Co. is a subsidiary of Takeda Pharmaceutical Co., Ltd. that functions as an investment holding British company. The company is based in London, UK.

Founded in 2014, Baxalta UK Ltd. is a subsidiary of Takeda Pharmaceutical Co., Ltd. that manufactures biopharmaceutical products. The company is based in London, UK.

Shire Pharmaceutical Contracts Ltd. develops medicines for patients with rare diseases. The company was incorporated on June 2, 1986 and is headquartered in London, the United Kingdom.

Part of Takeda Pharmaceutical Co., Ltd., Shire Pharmaceuticals Ltd. is a patient-focused, British innovation-driven pharmaceutical company. The company is based in London, UK. Takeda has a distinguished 240-year history and aspires to bring better health and a brighter future for people worldwide. Shire Pharmaceuticals was founded in 1986. The CEO is Flemming Ørnskov.

Part of Takeda Pharmaceutical Co., Ltd., Shire Pharmaceutical Development Ltd. is a British company that engages in research and development of pharmaceutical products. The company is based in London, UK. Founded in 1990.

Part of Takeda Pharmaceutical Co., Ltd., Auralis Ltd. is a British company that develops and manufactures pharmaceutical products. The company is based in London, UK. The company was founded in 2005 by Simon Peter Bryson. Auralis was acquired by Shire ViroPharma, Inc., part of Takeda Pharmaceutical Co., Ltd. from January 27, 2014 on May 28, 2010 for $28.95 million.